| 內容註: |
Part I. Why Consider Focal Therapy? -- 1. What is Focal Therapy for Prostate Cancer? A Guide for Patients -- 2. Evolution of Focal Therapy for Localized Breast Cancer: Lumpectomy -- 3. Image-targeted Therapy for Localized Kidney Cancer -- 4. The Patient's Perspective: What Does the Patient Want? -- Part II. Global Perspective of Active Surveillance (AS) and Focal Therapy (FT) -- 5. Intersection of AS and Radical Therapy: Opportunities for FT in North America. -- 6. FT and AS of Prostate Cancer - A European Perspective -- 7. FT and AS of Prostate Cancer in Southeast Asia and the East -- 8. FT Perception and Acceptance in South America -- Part III. The Focal Therapy Concept: Scientific Foundation -- 9. Understanding Tumor Biology and Pathology - Cancer Grade, Volume, and Spatial Location - as a Foundation for Focal Therapy -- 10. Identifying and Characterizing the Index Lesion -- 11. The Role of Molecular Techniques to Distinguish Low Grade from Lethal Cancers -- 12. Utilizing Biopsy-based Genomic Assays to Risk Stratify Patients for Active Treatment -- 13. Can Understanding and Utilizing the Tumor Microenvironment Enhance the Therapeutic Efficacy of FT? -- 14. Differences between MRI Visible vs Invisible Cancers: Biology and Outcomes -- Part IV. Prostate Imaging and Staging -- 15. PIRADS Reporting Standards and Limitations for Cancer Detection in the Peripheral Zone vs Transition Zone, PI-QUAL, and Standardization in MR Quality -- 16. Employing a Quality Improvement Program to Optimize mpMRI-directed Fusion Biopsy -- 17. Multiparametric Ultrasound for Prostate Imaging and Targeting -- 18. What is Necessary for FT Staging: Cross-sectional vs PET vs Nil? -- Part V. Image-Targeted Prostate Biopsy Techniques -- 19. mpMRI-TRUS Prostate Fusion Biopsy Commercial Systems -- 20. Comparison of Outcomes with Transperineal vs Transrectal Image-targeted Prostate Biopsy -- 21. Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize and Treat the mpMRI Invisible Lesion -- 22. Multi-parametric Ultrasound (mpUS) Biopsy -- 23. Diagnostic Performance of PET-based Targeted Fusion Biopsy in Prostate Cancer -- 24. Optimizing biopsy core quality for diagnosis -- Part VI. Patient Selection and Ablation Treatment Schema -- 25. Patient Selection: What Tumors Should Be Treated Based on Grade, Size, Location, Genetics and Risk Category? -- 26. Definitions and Common Terminology for Focal Prostate Ablation -- 27. Focal Therapy for Anterior Cancers -- 28. Office-based Outpatient Focal Therapy -- Part VII. Transperineal Technologies for Focal Therapy -- 29. Focal Brachytherapy and IMRT -- 30. In-bore Transperineal MRI-Guided Laser Ablation -- 31. Focal Cryoablation -- 32. Irreversible Electroporation for Partial Gland Ablation: Clinical Application and Outcomes -- 33. Photodynamic Therapy -- Part VIII. Transurethral Technologies for Focal Therapy -- 34. Role of TULSA as a Focal Therapy in Prostate Cancer -- 35. Transurethral Vapor Ablation in Prostate Cancer -- Part IX. Transrectal Technologies for Focal Therapy -- 36. Robotic High-Intensity Focused Ultrasound -- 37. Transrectal laser ablation of prostate cancer -- Part X. Post-treatment Assessment of Focal Therapy Outcomes -- 38. Role of Prostate MRI for Post-treatment Assessment and Surveillance -- 39. Measuring patient-based outcomes: setting realistic expectations when balancing functional outcomes with cancer control -- 40. Assessing Functional Outcomes after Focal Therapy -- 41. Biochemical Assessment of Cancer Outcomes following Focal Therapy -- 42. Pathologic Assessment and Implications following Prostate Focal Therapy -- 43. Salvage Options after Focal Therapy Recurrence -- Part XI. Looking forward -- 44. Design of Payment and Reimbursement Strategies for Focal Therapy for Acceptance in Value Based Care Models -- 45. The Horizon: Future of Focal Therapy in Prostate Cancer. |